Fig. 1.

Dipyridamole inhibits the sterol‐regulated feedback loop of the MVA pathway. Schematic representation of the MVA pathway. Statins inhibit the rate‐limiting enzyme of the pathway, HMGCR, which catalyzes the conversion of HMG‐CoA to MVA. MVA is subsequently used to synthesize various metabolites that are important for cell growth and survival, including GGPP and cholesterol. Statin‐mediated cholesterol depletion induces the cleavage and activation of SREBP2, which in turn induces the transcription of genes involved in MVA metabolism to restore homeostasis. We previously identified that the drug dipyridamole can inhibit statin‐induced SREBP2 activation; however, the mechanism by which dipyridamole inhibits SREBP2 cleavage remains poorly understood.